Mana.bio Secures $19.5M in for Advancing AI-Driven Drug Delivery Platform

Mana.bio, headquartered in Tel Aviv, Israel, a pioneering biotechnology company focusing on programmable drug delivery, successfully raised $19.5 million in seed financing. This funding round was co-led by prominent investors, including Andreessen Horowitz Bio + Health, Base4 Capital, NFX, LionBird, and Technion Institute of Technology. Mana.bio, led by Yogev Debbi (co-founder and CEO), Roy Nevo (co-founder and CTO), Avi Schroeder, PhD (scientific co-founder), and Kira Radinsky, PhD (scientific co-founder), is committed to leveraging AI to optimize lipid nanoparticles for tissue-specific delivery of nucleic acid-based therapeutics and vaccines. The funding will drive the further development of their cutting-edge AI LNP platform.